drug–device combination products are more complex. The regulations are more demanding. The opportunity is bigger than ever.
#CombinationProducts #MedicalDevices #Pharma #RegulatoryStrategy #DigitalHealth #ClinicalResearch

https://genelifecr.blogspot.com/2026/05/drugdevice-combination-products.html

In 2012, Genelife published a perspective on drug–device combination products.

The conclusion then: the benefits justify the complexity. The manufacturing model that made most sense: two distinct facilities, coordinated but separate.

Our updated perspective — what's changed, what hasn't, and what it means for your program — is now on the blog.

#DrugDeviceCombination #CombinationProducts #MedicalDevices #ClinicalResearch #RegulatoryStrategy #Pharma #DigitalHealth



https://genelifecr.blogspot.com/2026/05/drugdevice-combination-products.html

New regulations, shifting enforcement priorities, and accelerating AI and data use mean last year’s compliance playbook may fall short. The smartest teams are rethinking where legal can create leverage—not just manage risk. ZwillGen’s 2026 legal and compliance “resolutions” spotlight where in-house counsel should focus now to stay ahead.

#LegalCompliance #InHouseCounsel #RiskManagement #RegulatoryStrategy #LegalInnovation

https://www.zwillgen.com/practical-advice/zwillgens-new-years-resolutions-to-consider-in-2026/